Target intelligence / Profile preview

Transportin-3 (TNPO3)

Target
TNPO3
Molecular classification
Nuclear transport receptor, β-karyopherin family, Transporter
01

Overview

Transportin-3 (TNPO3) is a nuclear import receptor belonging to the β-karyopherin family, responsible for shuttling serine/arginine-rich (SR) proteins—especially splicing regulators—into the nucleus[1][4]. It is essential for correct pre-mRNA splicing and regulates RNA metabolism in various cell types[1][2][3]. TNPO3 also acts as an important cellular cofactor for HIV-1, facilitating the nuclear import of viral components necessary for HIV-1 replication[1][3]. Mutations in the TNPO3 gene cause autosomal dominant limb girdle muscular dystrophy type 1F (LGMD1F), reflecting its critical role in muscle and possibly other tissues[2][3]. Because of its functions in viral infection and splicing regulation, it is a potential but challenging therapeutic target.

Other names
Importin-12IPO12Transportin-SRTRN-SRTRN-SR2Imp12MTR10ALGMD1FLGMDD2limb girdle muscular dystrophy 1F (autosomal dominant)
02

Mechanism of action

Drugs or molecular inhibitors would likely block TNPO3's cargo recognition or nuclear import function, thereby affecting splicing factor localization and, e.g., impairing HIV-1 cofactor functions[1][3]

03

Biological functions

Nuclear import of serine/arginine-rich (SR) proteinsmRNA splicing regulationRNA metabolismCofactor in HIV-1 replication
04

Disease associations

Muscular dystrophy (specifically, limb girdle muscular dystrophy type 1F/2D)Infection (notably as a host factor in HIV-1 replication)Immune dysfunction (disrupted T cell development)
05

Safety considerations

Essential role in mRNA splicing and nuclear import suggests that systemic inhibition could cause widespread disruption of splicing and gene regulation, posing a risk of toxicity and tissue-specific effects[2][3]
06

Interacting drugs

None established; research targeting TNPO3 function for HIV/AIDS under investigation[1][3]
07

Biomarkers

Mutations in TNPO3 (for limb girdle muscular dystrophy 1F)[2][3]TNPO3 expression levels (potentially in some infection/immune contexts, mostly experimental)

Beyond the preview

Go deeper on Transportin-3 (TNPO3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transportin-3 (TNPO3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call